Univariate and multivariate HR for mortality and CV events for the 28- and the 8-sites scores
| Variables . | HR (95% CI), P-value . |
|---|---|
| Outcome: all-cause death | |
| Univariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.03 (1.01–1.05), 0.002 |
| 8-sites score (continuous, 5 US-B lines increase) | 1.10 (1.04–1.17), 0.002 |
| Multivariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.03 (1.01–1.05), 0.006 |
| 8-sites score (continuous, 5 US-B lines increase) | 1.09 (1.02–1.18), 0.01 |
| Outcome: CV events | |
| Univariate analysis | |
| 28-sites score (5 US-B lines increase) | 1.03 (1.01–1.04), 0.003 |
| 8-sites(5 US-B lines increase) | 1.10 (1.03–1.16), 0.002 |
| Multivariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.02 (1.00–1.04), 0.05 |
| 8-sites (continuous, 5 US-B lines increase) | 1.07 (1.00–1.14), 0.05 |
| Variables . | HR (95% CI), P-value . |
|---|---|
| Outcome: all-cause death | |
| Univariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.03 (1.01–1.05), 0.002 |
| 8-sites score (continuous, 5 US-B lines increase) | 1.10 (1.04–1.17), 0.002 |
| Multivariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.03 (1.01–1.05), 0.006 |
| 8-sites score (continuous, 5 US-B lines increase) | 1.09 (1.02–1.18), 0.01 |
| Outcome: CV events | |
| Univariate analysis | |
| 28-sites score (5 US-B lines increase) | 1.03 (1.01–1.04), 0.003 |
| 8-sites(5 US-B lines increase) | 1.10 (1.03–1.16), 0.002 |
| Multivariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.02 (1.00–1.04), 0.05 |
| 8-sites (continuous, 5 US-B lines increase) | 1.07 (1.00–1.14), 0.05 |
In the multivariate analysis, the hazard ratios (HRs) were adjusted for the full set of variables described in Table 1 (age, gender, current smoking, diabetes, cholesterol, arterial pressure, CV comorbidities, BMI, anti-hypertensive treatment, dialysis vintage, haemoglobin, albumin, calcium, phosphate and CRP).
Univariate and multivariate HR for mortality and CV events for the 28- and the 8-sites scores
| Variables . | HR (95% CI), P-value . |
|---|---|
| Outcome: all-cause death | |
| Univariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.03 (1.01–1.05), 0.002 |
| 8-sites score (continuous, 5 US-B lines increase) | 1.10 (1.04–1.17), 0.002 |
| Multivariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.03 (1.01–1.05), 0.006 |
| 8-sites score (continuous, 5 US-B lines increase) | 1.09 (1.02–1.18), 0.01 |
| Outcome: CV events | |
| Univariate analysis | |
| 28-sites score (5 US-B lines increase) | 1.03 (1.01–1.04), 0.003 |
| 8-sites(5 US-B lines increase) | 1.10 (1.03–1.16), 0.002 |
| Multivariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.02 (1.00–1.04), 0.05 |
| 8-sites (continuous, 5 US-B lines increase) | 1.07 (1.00–1.14), 0.05 |
| Variables . | HR (95% CI), P-value . |
|---|---|
| Outcome: all-cause death | |
| Univariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.03 (1.01–1.05), 0.002 |
| 8-sites score (continuous, 5 US-B lines increase) | 1.10 (1.04–1.17), 0.002 |
| Multivariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.03 (1.01–1.05), 0.006 |
| 8-sites score (continuous, 5 US-B lines increase) | 1.09 (1.02–1.18), 0.01 |
| Outcome: CV events | |
| Univariate analysis | |
| 28-sites score (5 US-B lines increase) | 1.03 (1.01–1.04), 0.003 |
| 8-sites(5 US-B lines increase) | 1.10 (1.03–1.16), 0.002 |
| Multivariate analysis | |
| 28-sites score (continuous, 5 US-B lines increase) | 1.02 (1.00–1.04), 0.05 |
| 8-sites (continuous, 5 US-B lines increase) | 1.07 (1.00–1.14), 0.05 |
In the multivariate analysis, the hazard ratios (HRs) were adjusted for the full set of variables described in Table 1 (age, gender, current smoking, diabetes, cholesterol, arterial pressure, CV comorbidities, BMI, anti-hypertensive treatment, dialysis vintage, haemoglobin, albumin, calcium, phosphate and CRP).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
